events_x,ast_method,resistance_gene_markers,country,n_esbl_positive,esbl_test,n_carbapenemase_positive,theme,breakpoint_standard,antibiotic,year_start,ssi_type,facility_level,year_end,mic_breakpoint_s,denominator_type,who_class,breakpoint_version,mic_breakpoint_r,readmission_window_days,outcome,n_mdr,specimen_type,ascertainment_window_days,surgical_specialty,mrsa_detection_method,reoperation_definition_text,sample_size_n,setting,n_xdr,carbapenemase_test,mic_unit,carbapenemase_genes,zone_diameter_unit,study_id,mdr_definition_text,pathogen
1163,,,"Benin, Ghana, India, Mexico, Nigeria, Rwanda, South Africa",,,,burden_incidence,,,2018.0,overall,mixed,2020.0,,patients,,,,,ssi_incidence,,,30.0,general,,,5284,hospital,,,,,,Varghese2024-Multicountry-FALCON-2018-2020-01,,
33,,,Ethiopia,,,,burden_incidence,,,2021.0,overall,tertiary,2021.0,,patients,,,,,ssi_incidence,,,30.0,obstetrics/gynecology,,,262,hospital,,,,,,Abayneh2022-Ethiopia-MizanTepi-2021-01,,
115,,,Ethiopia,,,,burden_incidence,,,2019.0,overall,tertiary,2019.0,,patients,,,,,ssi_incidence,,,30.0,general,,,165,hospital,,,,,,Abosse2021-Ethiopia-FelegeHiwot-2019-01,,
49,,,Ethiopia,,,,burden_incidence,,,2016.0,overall,tertiary,2016.0,,patients,,,,,ssi_incidence,,,30.0,general,,,338,hospital,,,,,,Ali2023-Ethiopia-DessieHospital-2016-01,,
41,,,Ethiopia,,,,burden_incidence,,,2016.0,overall,tertiary,2016.0,,patients,,,,,ssi_incidence,,,30.0,general,,,338,hospital,,,,,,Ali2023-Ethiopia-DessieHospital-2016-01,,
42,,,Ethiopia,,,,burden_incidence,,,2017.0,overall,tertiary,2017.0,,patients,,,,,ssi_incidence,,,30.0,general,,,255,hospital,,,,,,Billoro2019-Ethiopia-WUNEMMH-2017-01,,
15,,,Ethiopia,,,,burden_incidence,,,2017.0,overall,tertiary,2017.0,,procedures,,,,,ssi_incidence,,,30.0,general,,,144,hospital,,,,,,Billoro2019-Ethiopia-WUNEMMH-2017-01,,
27,,,Ethiopia,,,,burden_incidence,,,2017.0,overall,tertiary,2017.0,,procedures,,,,,ssi_incidence,,,30.0,general,,,111,hospital,,,,,,Billoro2019-Ethiopia-WUNEMMH-2017-01,,
29,,,Ethiopia,,,,burden_incidence,,,2023.0,overall,tertiary,2023.0,,patients,,,,,ssi_incidence,,,30.0,general,,,183,hospital,,,,,,Boru2025-Ethiopia-BuleHora-2023-01,,
45,,,Kenya,,,,burden_incidence,,,,overall,tertiary,,,patients,,,,,ssi_incidence,,,,general,,,62,hospital,,,,,,Burugu2022-Kenya-KenyattaNH-2022-01,,
12,,,Kenya,,,,burden_incidence,,,2008.0,overall,tertiary,2009.0,,procedures,,,,,ssi_incidence,,,30.0,general,,,171,hospital,,,,,,Dinda2013-Kenya-AKUHNairobi-20082009-1,,
39,,,Kenya,,,,burden_incidence,,,2008.0,overall,tertiary,2009.0,,procedures,,,,,ssi_incidence,,,30.0,general,,,268,hospital,,,,,,Dinda2013-Kenya-AKUHNairobi-20082009-1,,
5,,,Kenya,,,,burden_incidence,,,2008.0,overall,tertiary,2009.0,,procedures,,,,,ssi_incidence,,,30.0,general,,,91,hospital,,,,,,Dinda2013-Kenya-AKUHNairobi-20082009-1,,
7,,,Kenya,,,,burden_incidence,,,2008.0,overall,tertiary,2009.0,,procedures,,,,,ssi_incidence,,,30.0,general,,,80,hospital,,,,,,Dinda2013-Kenya-AKUHNairobi-20082009-1,,
6,,,Kenya,,,,burden_incidence,,,2008.0,overall,tertiary,2009.0,,procedures,,,,,ssi_incidence,,,30.0,general,,,30,hospital,,,,,,Dinda2013-Kenya-AKUHNairobi-20082009-1,,
20,,,Kenya,,,,burden_incidence,,,2008.0,overall,tertiary,2009.0,,procedures,,,,,ssi_incidence,,,30.0,general,,,67,hospital,,,,,,Dinda2013-Kenya-AKUHNairobi-20082009-1,,
225,,,Tanzania,,,,burden_incidence,,,2013.0,overall,tertiary,2013.0,,patients,,,,,ssi_incidence,,,30.0,obstetrics/gynecology,,,467,hospital,,,,,,Gentilotti2020-Tanzania-Dodoma-2013-2015-1,,
95,,,Tanzania,,,,burden_incidence,,,2015.0,overall,tertiary,2015.0,,patients,,,,,ssi_incidence,,,30.0,obstetrics/gynecology,,,573,hospital,,,,,,Gentilotti2020-Tanzania-Dodoma-2013-2015-1,,
138,,,Tanzania,,,,burden_incidence,,,2013.0,superficial,tertiary,2013.0,,patients,,,,,ssi_incidence,,,30.0,obstetrics/gynecology,,,225,hospital,,,,,,Gentilotti2020-Tanzania-Dodoma-2013-2015-1,,
74,,,Tanzania,,,,burden_incidence,,,2013.0,deep,tertiary,2013.0,,patients,,,,,ssi_incidence,,,30.0,obstetrics/gynecology,,,225,hospital,,,,,,Gentilotti2020-Tanzania-Dodoma-2013-2015-1,,
80,,,Tanzania,,,,burden_incidence,,,2015.0,superficial,tertiary,2015.0,,patients,,,,,ssi_incidence,,,30.0,obstetrics/gynecology,,,95,hospital,,,,,,Gentilotti2020-Tanzania-Dodoma-2013-2015-1,,
11,,,Tanzania,,,,burden_incidence,,,2015.0,deep,tertiary,2015.0,,patients,,,,,ssi_incidence,,,30.0,obstetrics/gynecology,,,95,hospital,,,,,,Gentilotti2020-Tanzania-Dodoma-2013-2015-1,,
126,,,Ethiopia,,,,burden_incidence,,,2022.0,overall,tertiary,2023.0,,patients,,,,,ssi_incidence,,,30.0,general,,,204,hospital,,,,,,Habteweld2023-Ethiopia-DebreBerhan-202210202301-01,,
73,,,Ethiopia,,,,burden_incidence,,,2022.0,superficial,tertiary,2023.0,,patients,,,,,ssi_incidence,,,30.0,general,,,126,hospital,,,,,,Habteweld2023-Ethiopia-DebreBerhan-202210202301-01,,
53,,,Ethiopia,,,,burden_incidence,,,2022.0,deep,tertiary,2023.0,,patients,,,,,ssi_incidence,,,30.0,general,,,126,hospital,,,,,,Habteweld2023-Ethiopia-DebreBerhan-202210202301-01,,
36,,,Tanzania,,,,burden_incidence,,,2024.0,overall,tertiary,2024.0,,patients,,,,,ssi_incidence,,,30.0,orthopedics,,,120,hospital,,,,,,Hamudu2025-Tanzania-BMC_SRHH-2024-01,,
23,,,Tanzania,,,,burden_incidence,,,2024.0,overall,tertiary,2024.0,,patients,,,,,ssi_incidence,,,30.0,orthopedics,,,90,hospital,,,,,,Hamudu2025-Tanzania-BMC_SRHH-2024-01,,
13,,,Tanzania,,,,burden_incidence,,,2024.0,overall,tertiary,2024.0,,patients,,,,,ssi_incidence,,,30.0,orthopedics,,,30,hospital,,,,,,Hamudu2025-Tanzania-BMC_SRHH-2024-01,,
28,,,Tanzania,,,,burden_incidence,,,2024.0,superficial,tertiary,2024.0,,patients,,,,,ssi_incidence,,,30.0,orthopedics,,,36,hospital,,,,,,Hamudu2025-Tanzania-BMC_SRHH-2024-01,,
8,,,Tanzania,,,,burden_incidence,,,2024.0,deep,tertiary,2024.0,,patients,,,,,ssi_incidence,,,30.0,orthopedics,,,36,hospital,,,,,,Hamudu2025-Tanzania-BMC_SRHH-2024-01,,
20,,,Malawi,,,,burden_incidence,,,2023.0,overall,tertiary,2023.0,,patients,,,,,ssi_incidence,,,30.0,obstetrics/gynecology,,,208,hospital,,,,,,Kachipedzu2024-Malawi-QECH-2023-1,,
19,,,Malawi,,,,burden_incidence,,,2023.0,superficial,tertiary,2023.0,,patients,,,,,ssi_incidence,,,30.0,obstetrics/gynecology,,,208,hospital,,,,,,Kachipedzu2024-Malawi-QECH-2023-1,,
1,,,Malawi,,,,burden_incidence,,,2023.0,deep,tertiary,2023.0,,patients,,,,,ssi_incidence,,,30.0,obstetrics/gynecology,,,208,hospital,,,,,,Kachipedzu2024-Malawi-QECH-2023-1,,
55,,,Ethiopia,,,,burden_incidence,,,2019.0,overall,tertiary,2020.0,,patients,,,,,ssi_incidence,,,30.0,general,,,281,hospital,,,,,,Kefale2020-Ethiopia-FinoteSelam-2019-2020-1,,
41,,,Ethiopia,,,,burden_incidence,,,2019.0,superficial,tertiary,2020.0,,patients,,,,,ssi_incidence,,,30.0,general,,,281,hospital,,,,,,Kefale2020-Ethiopia-FinoteSelam-2019-2020-1,,
8,,,Ethiopia,,,,burden_incidence,,,2019.0,deep,tertiary,2020.0,,patients,,,,,ssi_incidence,,,30.0,general,,,281,hospital,,,,,,Kefale2020-Ethiopia-FinoteSelam-2019-2020-1,,
8,,,Ethiopia,,,,burden_incidence,,,2019.0,organ_space,tertiary,2020.0,,patients,,,,,ssi_incidence,,,30.0,general,,,281,hospital,,,,,,Kefale2020-Ethiopia-FinoteSelam-2019-2020-1,,
169,,,Cameroon,,,,burden_incidence,,,2010.0,overall,mixed,2011.0,,patients,,,,,ssi_incidence,,,,general,,,212,hospital,,,,,,Akoachere2014-Cameroon-Buea-201010201103-01,,
3,,,Cameroon,,,,burden_incidence,,,2010.0,overall,mixed,2011.0,,patients,,,,,ssi_incidence,,,,general,,,3,hospital,,,,,,Akoachere2014-Cameroon-Buea-201010201103-01,,
13,,,Cameroon,,,,burden_incidence,,,2010.0,overall,mixed,2011.0,,patients,,,,,ssi_incidence,,,,general,,,15,hospital,,,,,,Akoachere2014-Cameroon-Buea-201010201103-01,,
23,,,Cameroon,,,,burden_incidence,,,2010.0,overall,mixed,2011.0,,patients,,,,,ssi_incidence,,,,general,,,29,hospital,,,,,,Akoachere2014-Cameroon-Buea-201010201103-01,,
130,,,Cameroon,,,,burden_incidence,,,2010.0,overall,mixed,2011.0,,patients,,,,,ssi_incidence,,,,general,,,165,hospital,,,,,,Akoachere2014-Cameroon-Buea-201010201103-01,,
96,,,Ethiopia,,,,burden_incidence,,,2012.0,overall,tertiary,2012.0,,patients,,,,,ssi_incidence,,,30.0,general,,,128,hospital,,,,,,Mengesha2014-Ethiopia-Ayder-2012-1,,
53,,,Ethiopia,,,,burden_incidence,,,2019.0,overall,tertiary,2019.0,,patients,,,,,ssi_incidence,,,30.0,general,,,251,hospital,,,,,,Misha2021-Ethiopia-JimmaMedicalCenter-2019-01,,
34,,,Rwanda,,,,burden_incidence,,,2017.0,superficial,tertiary,2018.0,,patients,,,,,ssi_incidence,,,30.0,general,,,294,hospital,,,,,,Mukagendaneza2019-Rwanda-KigaliCHUK-2017_2018-01,,
26,,,Rwanda,,,,burden_incidence,,,2017.0,superficial,tertiary,2018.0,,patients,,,,,ssi_incidence,,,30.0,orthopedics,,,217,hospital,,,,,,Mukagendaneza2019-Rwanda-KigaliCHUK-2017_2018-01,,
8,,,Rwanda,,,,burden_incidence,,,2017.0,superficial,tertiary,2018.0,,patients,,,,,ssi_incidence,,,30.0,general,,,66,hospital,,,,,,Mukagendaneza2019-Rwanda-KigaliCHUK-2017_2018-01,,
0,,,Rwanda,,,,burden_incidence,,,2017.0,superficial,tertiary,2018.0,,patients,,,,,ssi_incidence,,,30.0,urology,,,11,hospital,,,,,,Mukagendaneza2019-Rwanda-KigaliCHUK-2017_2018-01,,
225,,,Tanzania,,,,burden_incidence,,,2013.0,overall,tertiary,2013.0,,patients,,,,,ssi_incidence,,,30.0,obstetrics/gynecology,,,467,hospital,,,,,,DeNardo2016-Tanzania-Dodoma-2013-1,,
138,,,Tanzania,,,,burden_incidence,,,2013.0,superficial,tertiary,2013.0,,patients,,,,,ssi_incidence,,,30.0,obstetrics/gynecology,,,467,hospital,,,,,,DeNardo2016-Tanzania-Dodoma-2013-1,,
69,,,Tanzania,,,,burden_incidence,,,2013.0,deep,tertiary,2013.0,,patients,,,,,ssi_incidence,,,30.0,obstetrics/gynecology,,,467,hospital,,,,,,DeNardo2016-Tanzania-Dodoma-2013-1,,
5,,,Tanzania,,,,burden_incidence,,,2013.0,organ_space,tertiary,2013.0,,patients,,,,,ssi_incidence,,,30.0,obstetrics/gynecology,,,467,hospital,,,,,,DeNardo2016-Tanzania-Dodoma-2013-1,,
8,,,Rwanda,,,,burden_incidence,,,2015.0,overall,secondary,2016.0,,patients,,,,,ssi_incidence,,,30.0,obstetrics/gynecology,,,147,hospital,,,,,,Ntirushwa2021-Rwanda-RuhengeriHospital-2015-2016-01,,
4,,,Rwanda,,,,burden_incidence,,,2015.0,overall,secondary,2016.0,,patients,,,,,ssi_incidence,,,30.0,obstetrics/gynecology,,,154,hospital,,,,,,Ntirushwa2021-Rwanda-RuhengeriHospital-2015-2016-01,,
12,,,Rwanda,,,,burden_incidence,,,2015.0,overall,secondary,2016.0,,patients,,,,,ssi_incidence,,,30.0,obstetrics/gynecology,,,301,hospital,,,,,,Ntirushwa2021-Rwanda-RuhengeriHospital-2015-2016-01,,
20,,,Gabon,,,,burden_incidence,,,2009.0,overall,tertiary,2009.0,,patients,,,,,ssi_incidence,,,,general,,,2925,hospital,,,,,,Scherbaum2014-Gabon-Lambarene-2009-01,,
20,,,Gabon,,,,burden_incidence,,,2009.0,overall,tertiary,2009.0,,procedures,,,,,ssi_incidence,,,,general,,,1059,hospital,,,,,,Scherbaum2014-Gabon-Lambarene-2009-01,,
3,,,Gabon,,,,burden_incidence,,,2009.0,overall,tertiary,2009.0,,procedures,,,,,ssi_incidence,,,,obstetrics/gynecology,,,26,hospital,,,,,,Scherbaum2014-Gabon-Lambarene-2009-01,,
5,,,Gabon,,,,burden_incidence,,,2009.0,overall,tertiary,2009.0,,procedures,,,,,ssi_incidence,,,,obstetrics/gynecology,,,80,hospital,,,,,,Scherbaum2014-Gabon-Lambarene-2009-01,,
45,,,Rwanda,,,,burden_incidence,,,2019.0,overall,secondary,2020.0,,patients,,,,,ssi_incidence,,,11.0,obstetrics/gynecology,,,795,hospital,,,,,,Velin2021-Rwanda-KireheDistrictHospital-2019_2020-01,,
109,,,Uganda,,,,burden_incidence,,,2017.0,overall,tertiary,2018.0,,patients,,,,,ssi_incidence,,,30.0,obstetrics/gynecology,,,109,hospital,,,,,,Wekesa2020-Uganda-MulagoHospital-201711201804-01,,
752,,,Ethiopia,,,,burden_incidence,,,2020.0,overall,tertiary,2021.0,,patients,,,,,ssi_incidence,,,30.0,general,,,752,hospital,,,,,,Worku2023-Ethiopia-Multicentre-2020-2021-1,,
493,,,Ethiopia,,,,burden_incidence,,,2020.0,,tertiary,2021.0,,patients,,,,,ssi_incidence,,,30.0,general,,,752,hospital,,,,,,Worku2023-Ethiopia-Multicentre-2020-2021-1,,
12,disk_diffusion,,Ethiopia,,,,amr_prevalence,CLSI,ampicillin,2021.0,,tertiary,2021.0,,isolates,critically_important,CLSI 2018,,,amr_prevalence,12.0,wound_swab,,,,,12,hospital,,,,,mm,Abayneh2022-Ethiopia-MizanTepi-2021-01,Resistance to three or more classes of antibiotics.,Escherichia coli
7,disk_diffusion,,Ethiopia,,,,amr_prevalence,CLSI,ampicillin,2021.0,,tertiary,2021.0,,isolates,critically_important,CLSI 2018,,,amr_prevalence,8.0,wound_swab,,,cefoxitin disk,,8,hospital,,,,,mm,Abayneh2022-Ethiopia-MizanTepi-2021-01,Resistance to three or more classes of antibiotics.,Staphylococcus aureus
11,disk_diffusion,,Ethiopia,,,,amr_prevalence,CLSI,amoxicillin-clavulanate,2021.0,,tertiary,2021.0,,isolates,critically_important,CLSI 2018,,,amr_prevalence,12.0,wound_swab,,,,,12,hospital,,,,,mm,Abayneh2022-Ethiopia-MizanTepi-2021-01,Resistance to three or more classes of antibiotics.,Escherichia coli
3,disk_diffusion,,Ethiopia,,,,amr_prevalence,CLSI,cefoxitin,2021.0,,tertiary,2021.0,,isolates,critically_important,CLSI 2018,,,amr_prevalence,8.0,wound_swab,,,cefoxitin disk,,8,hospital,,,,,mm,Abayneh2022-Ethiopia-MizanTepi-2021-01,Resistance to three or more classes of antibiotics.,Staphylococcus aureus
27,disk_diffusion,,Ethiopia,,,,amr_prevalence,CLSI,amoxicillin,2019.0,,tertiary,2019.0,,isolates,important,CLSI 2018,,,amr_prevalence,,wound_swab,,,,,31,hospital,,,,,mm,Abosse2021-Ethiopia-FelegeHiwot-2019-01,MDR was defined as the ability of an isolate to resist >3 antimicrobial agents in different class.,Staphylococcus aureus
22,disk_diffusion,,Ethiopia,,,,amr_prevalence,CLSI,ampicillin,2019.0,,tertiary,2019.0,,isolates,important,CLSI 2018,,,amr_prevalence,,wound_swab,,,,,31,hospital,,,,,mm,Abosse2021-Ethiopia-FelegeHiwot-2019-01,MDR was defined as the ability of an isolate to resist >3 antimicrobial agents in different class.,Staphylococcus aureus
3,disk_diffusion,,Ethiopia,,,,amr_prevalence,CLSI,vancomycin,2019.0,,tertiary,2019.0,,isolates,critically_important,CLSI 2018,,,amr_prevalence,,wound_swab,,,,,31,hospital,,,,,mm,Abosse2021-Ethiopia-FelegeHiwot-2019-01,MDR was defined as the ability of an isolate to resist >3 antimicrobial agents in different class.,Staphylococcus aureus
5,disk_diffusion,,Ethiopia,,,,amr_prevalence,CLSI,ciprofloxacin,2019.0,,tertiary,2019.0,,isolates,critically_important,CLSI 2018,,,amr_prevalence,,wound_swab,,,,,31,hospital,,,,,mm,Abosse2021-Ethiopia-FelegeHiwot-2019-01,MDR was defined as the ability of an isolate to resist >3 antimicrobial agents in different class.,Staphylococcus aureus
22,disk_diffusion,,Ethiopia,,,,amr_prevalence,CLSI,ampicillin,2019.0,,tertiary,2019.0,,isolates,important,CLSI 2018,,,amr_prevalence,,wound_swab,,,,,26,hospital,,,,,mm,Abosse2021-Ethiopia-FelegeHiwot-2019-01,MDR was defined as the ability of an isolate to resist >3 antimicrobial agents in different class.,Pseudomonas aeruginosa
5,disk_diffusion,,Ethiopia,,,,amr_prevalence,CLSI,ciprofloxacin,2019.0,,tertiary,2019.0,,isolates,critically_important,CLSI 2018,,,amr_prevalence,,wound_swab,,,,,26,hospital,,,,,mm,Abosse2021-Ethiopia-FelegeHiwot-2019-01,MDR was defined as the ability of an isolate to resist >3 antimicrobial agents in different class.,Pseudomonas aeruginosa
6,disk_diffusion,,Ethiopia,,,,amr_prevalence,CLSI,meropenem,2019.0,,tertiary,2019.0,,isolates,critically_important,CLSI 2018,,,amr_prevalence,,wound_swab,,,,,26,hospital,,,,,mm,Abosse2021-Ethiopia-FelegeHiwot-2019-01,MDR was defined as the ability of an isolate to resist >3 antimicrobial agents in different class.,Pseudomonas aeruginosa
14,disk_diffusion,,Ethiopia,,,,amr_prevalence,CLSI,ampicillin,2019.0,,tertiary,2019.0,,isolates,important,CLSI 2018,,,amr_prevalence,,wound_swab,,,,,17,hospital,,,,,mm,Abosse2021-Ethiopia-FelegeHiwot-2019-01,MDR was defined as the ability of an isolate to resist >3 antimicrobial agents in different class.,Klebsiella spp.
2,disk_diffusion,,Ethiopia,,,,amr_prevalence,CLSI,meropenem,2019.0,,tertiary,2019.0,,isolates,critically_important,CLSI 2018,,,amr_prevalence,,wound_swab,,,,,17,hospital,,,,,mm,Abosse2021-Ethiopia-FelegeHiwot-2019-01,MDR was defined as the ability of an isolate to resist >3 antimicrobial agents in different class.,Klebsiella spp.
2,disk_diffusion,,Ethiopia,,,,amr_prevalence,CLSI,gentamicin,2019.0,,tertiary,2019.0,,isolates,critically_important,CLSI 2018,,,amr_prevalence,,wound_swab,,,,,17,hospital,,,,,mm,Abosse2021-Ethiopia-FelegeHiwot-2019-01,MDR was defined as the ability of an isolate to resist >3 antimicrobial agents in different class.,Klebsiella spp.
14,disk_diffusion,,Ethiopia,,,,amr_prevalence,CLSI,penicillin,2016.0,,tertiary,2016.0,,isolates,important,CLSI M100-S24,,,amr_prevalence,9.0,wound_swab,,,Cefoxitin (30 μg) disk diffusion; zone diameter ≤21 mm considered resistant,,14,hospital,,,,,mm,Ali2023-Ethiopia-DessieHospital-2016-01,ECDC: non-susceptible to at least one agent in three or more antimicrobial categories.,Staphylococcus aureus
6,disk_diffusion,,Ethiopia,,,,amr_prevalence,CLSI,cefoxitin,2016.0,,tertiary,2016.0,,isolates,important,CLSI M100-S24,,,amr_prevalence,9.0,wound_swab,,,Cefoxitin (30 μg) disk diffusion; zone diameter ≤21 mm considered resistant,,14,hospital,,,,,mm,Ali2023-Ethiopia-DessieHospital-2016-01,ECDC: non-susceptible to at least one agent in three or more antimicrobial categories.,Staphylococcus aureus
8,disk_diffusion,,Ethiopia,6.0,Double disc approximation method,,amr_prevalence,CLSI,ampicillin,2016.0,,tertiary,2016.0,,isolates,important,CLSI M100-S24,,,amr_prevalence,8.0,wound_swab,,,,,9,hospital,,,,,mm,Ali2023-Ethiopia-DessieHospital-2016-01,ECDC: non-susceptible to at least one agent in three or more antimicrobial categories.,Escherichia coli
7,disk_diffusion,,Ethiopia,2.0,Double disc approximation method,,amr_prevalence,CLSI,ampicillin,2016.0,,tertiary,2016.0,,isolates,important,CLSI M100-S24,,,amr_prevalence,7.0,wound_swab,,,,,7,hospital,,,,,mm,Ali2023-Ethiopia-DessieHospital-2016-01,ECDC: non-susceptible to at least one agent in three or more antimicrobial categories.,Klebsiella pneumoniae
21,disk_diffusion,,Ethiopia,,,,amr_prevalence,CLSI,ampicillin,2016.0,,tertiary,2016.0,,isolates,important,CLSI M100-S24,,,amr_prevalence,,wound_swab,,,,,23,hospital,,,,,mm,Ali2023-Ethiopia-DessieHospital-2016-01,ECDC: non-susceptible to at least one agent in three or more antimicrobial categories.,Enterobacteriaceae
2,disk_diffusion,,Kenya,,,,amr_prevalence,CLSI,vancomycin,2018.0,,tertiary,2019.0,,isolates,important,CLSI 2016,,,amr_prevalence,,wound_swab,,,Oxacillin disk diffusion,,22,hospital,,,,,mm,Amulioto2020-Kenya-MamaLucyKibaki-2018-2019-1,,Staphylococcus aureus
3,disk_diffusion,,Kenya,,,,amr_prevalence,CLSI,ciprofloxacin,2018.0,,tertiary,2019.0,,isolates,critically_important,CLSI 2016,,,amr_prevalence,,wound_swab,,,Oxacillin disk diffusion,,22,hospital,,,,,mm,Amulioto2020-Kenya-MamaLucyKibaki-2018-2019-1,,Staphylococcus aureus
1,disk_diffusion,,Kenya,,,,amr_prevalence,CLSI,chloramphenicol,2018.0,,tertiary,2019.0,,isolates,highly_important,CLSI 2016,,,amr_prevalence,,wound_swab,,,Oxacillin disk diffusion,,22,hospital,,,,,mm,Amulioto2020-Kenya-MamaLucyKibaki-2018-2019-1,,Staphylococcus aureus
21,disk_diffusion,,Kenya,,,,amr_prevalence,CLSI,ampicillin,2018.0,,tertiary,2019.0,,isolates,highly_important,CLSI 2016,,,amr_prevalence,,wound_swab,,,Oxacillin disk diffusion,,22,hospital,,,,,mm,Amulioto2020-Kenya-MamaLucyKibaki-2018-2019-1,,Staphylococcus aureus
13,disk_diffusion,,Kenya,,,,amr_prevalence,CLSI,oxacillin,2018.0,,tertiary,2019.0,,isolates,highly_important,CLSI 2016,,,amr_prevalence,,wound_swab,,,Oxacillin disk diffusion,,22,hospital,,,,,mm,Amulioto2020-Kenya-MamaLucyKibaki-2018-2019-1,,Staphylococcus aureus
7,disk_diffusion,,Kenya,,,,amr_prevalence,CLSI,chloramphenicol,2018.0,,tertiary,2019.0,,isolates,highly_important,CLSI 2016,,,amr_prevalence,,wound_swab,,,,,12,hospital,,,,,mm,Amulioto2020-Kenya-MamaLucyKibaki-2018-2019-1,Multi-drug resistance (resistance to ≥ 4 antibiotics) observed with E. coli.,Escherichia coli
11,disk_diffusion,,Kenya,,,,amr_prevalence,CLSI,ampicillin,2018.0,,tertiary,2019.0,,isolates,highly_important,CLSI 2016,,,amr_prevalence,,wound_swab,,,,,12,hospital,,,,,mm,Amulioto2020-Kenya-MamaLucyKibaki-2018-2019-1,Multi-drug resistance (resistance to ≥ 4 antibiotics) observed with E. coli.,Escherichia coli
6,disk_diffusion,,Kenya,,,,amr_prevalence,CLSI,amikacin,2018.0,,tertiary,2019.0,,isolates,critically_important,CLSI 2016,,,amr_prevalence,,wound_swab,,,,,11,hospital,,,,,mm,Amulioto2020-Kenya-MamaLucyKibaki-2018-2019-1,,Acinetobacter baumannii
1,disk_diffusion,,Ethiopia,,,,amr_prevalence,CLSI,ceftriaxone,2017.0,,tertiary,2017.0,,isolates,critically_important,,,,amr_prevalence,,wound_swab,,,,,9,hospital,,,,,mm,Billoro2019-Ethiopia-WUNEMMH-2017-01,,Klebsiella pneumoniae
1,disk_diffusion,,Ethiopia,,,,amr_prevalence,CLSI,ciprofloxacin,2017.0,,tertiary,2017.0,,isolates,critically_important,,,,amr_prevalence,,wound_swab,,,,,9,hospital,,,,,mm,Billoro2019-Ethiopia-WUNEMMH-2017-01,,Klebsiella pneumoniae
3,disk_diffusion,,Ethiopia,,,,amr_prevalence,CLSI,gentamicin,2017.0,,tertiary,2017.0,,isolates,critically_important,,,,amr_prevalence,,wound_swab,,,,,9,hospital,,,,,mm,Billoro2019-Ethiopia-WUNEMMH-2017-01,,Klebsiella pneumoniae
2,disk_diffusion,,Ethiopia,,,,amr_prevalence,CLSI,chloramphenicol,2017.0,,tertiary,2017.0,,isolates,highly_important,,,,amr_prevalence,,wound_swab,,,,,6,hospital,,,,,mm,Billoro2019-Ethiopia-WUNEMMH-2017-01,,Klebsiella pneumoniae
0,disk_diffusion,,Ethiopia,,,,amr_prevalence,CLSI,ceftriaxone,2017.0,,tertiary,2017.0,,isolates,critically_important,,,,amr_prevalence,,wound_swab,,,,,3,hospital,,,,,mm,Billoro2019-Ethiopia-WUNEMMH-2017-01,,Staphylococcus aureus
1,disk_diffusion,,Ethiopia,,,,amr_prevalence,CLSI,ciprofloxacin,2017.0,,tertiary,2017.0,,isolates,critically_important,,,,amr_prevalence,,wound_swab,,,,,4,hospital,,,,,mm,Billoro2019-Ethiopia-WUNEMMH-2017-01,,Staphylococcus aureus
1,disk_diffusion,,Ethiopia,,,,amr_prevalence,CLSI,chloramphenicol,2023.0,,tertiary,2023.0,,isolates,highly_important,,,,amr_prevalence,8.0,wound_swab,,,Cefoxitin disk diffusion,,14,hospital,,,,,mm,Boru2025-Ethiopia-BuleHora-2023-01,Resistance to ≥3 classes of antimicrobials,Staphylococcus aureus
8,disk_diffusion,,Ethiopia,,,,amr_prevalence,CLSI,cefoxitin,2023.0,,tertiary,2023.0,,isolates,critically_important,,,,amr_prevalence,8.0,wound_swab,,,Cefoxitin disk diffusion,,14,hospital,,,,,mm,Boru2025-Ethiopia-BuleHora-2023-01,Resistance to ≥3 classes of antimicrobials,Staphylococcus aureus
8,disk_diffusion,,Ethiopia,,,,amr_prevalence,CLSI,penicillin,2023.0,,tertiary,2023.0,,isolates,critically_important,,,,amr_prevalence,8.0,wound_swab,,,Cefoxitin disk diffusion,,14,hospital,,,,,mm,Boru2025-Ethiopia-BuleHora-2023-01,Resistance to ≥3 classes of antimicrobials,Staphylococcus aureus
5,disk_diffusion,,Ethiopia,,,,amr_prevalence,CLSI,ampicillin,2023.0,,tertiary,2023.0,,isolates,critically_important,,,,amr_prevalence,3.0,wound_swab,,,,,6,hospital,,,,,mm,Boru2025-Ethiopia-BuleHora-2023-01,Resistance to ≥3 classes of antimicrobials,Escherichia coli
5,disk_diffusion,,Ethiopia,,,,amr_prevalence,CLSI,ceftazidime,2023.0,,tertiary,2023.0,,isolates,critically_important,,,,amr_prevalence,3.0,wound_swab,,,,,6,hospital,,,,,mm,Boru2025-Ethiopia-BuleHora-2023-01,Resistance to ≥3 classes of antimicrobials,Escherichia coli
0,disk_diffusion,,Ethiopia,,,,amr_prevalence,CLSI,ciprofloxacin,2023.0,,tertiary,2023.0,,isolates,critically_important,,,,amr_prevalence,3.0,wound_swab,,,,,6,hospital,,,,,mm,Boru2025-Ethiopia-BuleHora-2023-01,Resistance to ≥3 classes of antimicrobials,Pseudomonas aeruginosa
11,disk_diffusion,,Kenya,,,,amr_prevalence,study_defined,ceftriaxone,,,tertiary,,,isolates,critically_important,,,,amr_prevalence,,wound_swab,,,,,12,hospital,,,,,mm,Burugu2022-Kenya-KenyattaNH-2022-01,,Escherichia coli
3,disk_diffusion,,Kenya,,,,amr_prevalence,study_defined,ceftriaxone,,,tertiary,,,isolates,critically_important,,,,amr_prevalence,,wound_swab,,,,,4,hospital,,,,,mm,Burugu2022-Kenya-KenyattaNH-2022-01,,Proteus spp.
9,disk_diffusion,,Kenya,,,,amr_prevalence,study_defined,oxacillin,,,tertiary,,,isolates,critically_important,,,,amr_prevalence,,wound_swab,,,oxacillin disc,,16,hospital,,,,,mm,Burugu2022-Kenya-KenyattaNH-2022-01,,Staphylococcus aureus
3,disk_diffusion,,Kenya,,,,amr_prevalence,study_defined,vancomycin,,,tertiary,,,isolates,critically_important,,,,amr_prevalence,,wound_swab,,,,,4,hospital,,,,,mm,Burugu2022-Kenya-KenyattaNH-2022-01,,Enterococcus faecalis
6,disk_diffusion,,Kenya,,,,amr_prevalence,CLSI,ampicillin,2008.0,,tertiary,2009.0,,isolates,important,2009,,,amr_prevalence,,pus_swab,,,,,10,hospital,,,,,,Dinda2013-Kenya-AKUHNairobi-20082009-1,,Staphylococcus aureus
4,,,Kenya,,,,amr_prevalence,,doxycycline,2008.0,,tertiary,2009.0,,isolates,highly_important,,,,amr_prevalence,,,,,,,10,hospital,,,,,,Dinda2013-Kenya-AKUHNairobi-20082009-1,,Staphylococcus aureus
3,,,Kenya,,,,amr_prevalence,,azithromycin,2008.0,,tertiary,2009.0,,isolates,highly_important,,,,amr_prevalence,,,,,,,10,hospital,,,,,,Dinda2013-Kenya-AKUHNairobi-20082009-1,,Staphylococcus aureus
1,,,Kenya,,,,amr_prevalence,,amoxicillin-clavulanate,2008.0,,tertiary,2009.0,,isolates,highly_important,,,,amr_prevalence,,,,,,,10,hospital,,,,,,Dinda2013-Kenya-AKUHNairobi-20082009-1,,Staphylococcus aureus
1,,,Kenya,,,,amr_prevalence,,cefuroxime,2008.0,,tertiary,2009.0,,isolates,highly_important,,,,amr_prevalence,,,,,,,10,hospital,,,,,,Dinda2013-Kenya-AKUHNairobi-20082009-1,,Staphylococcus aureus
5,,,Kenya,,,,amr_prevalence,,ciprofloxacin,2008.0,,tertiary,2009.0,,isolates,critically_important,,,,amr_prevalence,,,,,,,10,hospital,,,,,,Dinda2013-Kenya-AKUHNairobi-20082009-1,,Staphylococcus aureus
2,,,Kenya,,,,amr_prevalence,,chloramphenicol,2008.0,,tertiary,2009.0,,isolates,highly_important,,,,amr_prevalence,,,,,,,10,hospital,,,,,,Dinda2013-Kenya-AKUHNairobi-20082009-1,,Staphylococcus aureus
1,,,Kenya,,,,amr_prevalence,,oxacillin,2008.0,,tertiary,2009.0,,isolates,highly_important,,,,amr_prevalence,,,,,oxacillin_disk_diffusion,,10,hospital,,,,,,Dinda2013-Kenya-AKUHNairobi-20082009-1,,Staphylococcus aureus
0,,,Kenya,,,,amr_prevalence,,netilmicin,2008.0,,tertiary,2009.0,,isolates,highly_important,,,,amr_prevalence,,,,,,,10,hospital,,,,,,Dinda2013-Kenya-AKUHNairobi-20082009-1,,Staphylococcus aureus
0,,,Kenya,,,,amr_prevalence,,vancomycin,2008.0,,tertiary,2009.0,,isolates,critically_important,,,,amr_prevalence,,,,,,,10,hospital,,,,,,Dinda2013-Kenya-AKUHNairobi-20082009-1,,Staphylococcus aureus
4,,,Kenya,,,,amr_prevalence,,ampicillin,2008.0,,tertiary,2009.0,,isolates,important,,,,amr_prevalence,,,,,,,5,hospital,,,,,,Dinda2013-Kenya-AKUHNairobi-20082009-1,,Coagulase-negative staphylococci
3,,,Kenya,,,,amr_prevalence,,doxycycline,2008.0,,tertiary,2009.0,,isolates,highly_important,,,,amr_prevalence,,,,,,,5,hospital,,,,,,Dinda2013-Kenya-AKUHNairobi-20082009-1,,Coagulase-negative staphylococci
3,,,Kenya,,,,amr_prevalence,,azithromycin,2008.0,,tertiary,2009.0,,isolates,highly_important,,,,amr_prevalence,,,,,,,5,hospital,,,,,,Dinda2013-Kenya-AKUHNairobi-20082009-1,,Coagulase-negative staphylococci
2,,,Kenya,,,,amr_prevalence,,amoxicillin-clavulanate,2008.0,,tertiary,2009.0,,isolates,highly_important,,,,amr_prevalence,,,,,,,5,hospital,,,,,,Dinda2013-Kenya-AKUHNairobi-20082009-1,,Coagulase-negative staphylococci
3,,,Kenya,,,,amr_prevalence,,cefuroxime,2008.0,,tertiary,2009.0,,isolates,highly_important,,,,amr_prevalence,,,,,,,5,hospital,,,,,,Dinda2013-Kenya-AKUHNairobi-20082009-1,,Coagulase-negative staphylococci
1,,,Kenya,,,,amr_prevalence,,ciprofloxacin,2008.0,,tertiary,2009.0,,isolates,critically_important,,,,amr_prevalence,,,,,,,5,hospital,,,,,,Dinda2013-Kenya-AKUHNairobi-20082009-1,,Coagulase-negative staphylococci
2,,,Kenya,,,,amr_prevalence,,chloramphenicol,2008.0,,tertiary,2009.0,,isolates,highly_important,,,,amr_prevalence,,,,,,,5,hospital,,,,,,Dinda2013-Kenya-AKUHNairobi-20082009-1,,Coagulase-negative staphylococci
0,,,Kenya,,,,amr_prevalence,,oxacillin,2008.0,,tertiary,2009.0,,isolates,highly_important,,,,amr_prevalence,,,,,,,5,hospital,,,,,,Dinda2013-Kenya-AKUHNairobi-20082009-1,,Coagulase-negative staphylococci
0,,,Kenya,,,,amr_prevalence,,netilmicin,2008.0,,tertiary,2009.0,,isolates,highly_important,,,,amr_prevalence,,,,,,,5,hospital,,,,,,Dinda2013-Kenya-AKUHNairobi-20082009-1,,Coagulase-negative staphylococci
0,,,Kenya,,,,amr_prevalence,,vancomycin,2008.0,,tertiary,2009.0,,isolates,critically_important,,,,amr_prevalence,,,,,,,5,hospital,,,,,,Dinda2013-Kenya-AKUHNairobi-20082009-1,,Coagulase-negative staphylococci
0,,,Kenya,,,,amr_prevalence,,co-trimoxazole,2008.0,,tertiary,2009.0,,isolates,highly_important,,,,amr_prevalence,,,,,,,4,hospital,,,,,,Dinda2013-Kenya-AKUHNairobi-20082009-1,,Kluyvera spp.
3,,,Kenya,,,,amr_prevalence,,doxycycline,2008.0,,tertiary,2009.0,,isolates,highly_important,,,,amr_prevalence,,,,,,,4,hospital,,,,,,Dinda2013-Kenya-AKUHNairobi-20082009-1,,Kluyvera spp.
2,,,Kenya,,,,amr_prevalence,,amoxicillin-clavulanate,2008.0,,tertiary,2009.0,,isolates,highly_important,,,,amr_prevalence,,,,,,,4,hospital,,,,,,Dinda2013-Kenya-AKUHNairobi-20082009-1,,Kluyvera spp.
2,,,Kenya,,,,amr_prevalence,,cefotaxime,2008.0,,tertiary,2009.0,,isolates,critically_important,,,,amr_prevalence,,,,,,,4,hospital,,,,,,Dinda2013-Kenya-AKUHNairobi-20082009-1,,Kluyvera spp.
1,,,Kenya,,,,amr_prevalence,,chloramphenicol,2008.0,,tertiary,2009.0,,isolates,highly_important,,,,amr_prevalence,,,,,,,4,hospital,,,,,,Dinda2013-Kenya-AKUHNairobi-20082009-1,,Kluyvera spp.
1,,,Kenya,,,,amr_prevalence,,cefuroxime,2008.0,,tertiary,2009.0,,isolates,highly_important,,,,amr_prevalence,,,,,,,4,hospital,,,,,,Dinda2013-Kenya-AKUHNairobi-20082009-1,,Kluyvera spp.
1,,,Kenya,,,,amr_prevalence,,ciprofloxacin,2008.0,,tertiary,2009.0,,isolates,critically_important,,,,amr_prevalence,,,,,,,4,hospital,,,,,,Dinda2013-Kenya-AKUHNairobi-20082009-1,,Kluyvera spp.
1,,,Kenya,,,,amr_prevalence,,gentamicin,2008.0,,tertiary,2009.0,,isolates,highly_important,,,,amr_prevalence,,,,,,,4,hospital,,,,,,Dinda2013-Kenya-AKUHNairobi-20082009-1,,Kluyvera spp.
3,,,Kenya,,,,amr_prevalence,,co-trimoxazole,2008.0,,tertiary,2009.0,,isolates,highly_important,,,,amr_prevalence,,,,,,,4,hospital,,,,,,Dinda2013-Kenya-AKUHNairobi-20082009-1,,Escherichia coli
3,,,Kenya,,,,amr_prevalence,,doxycycline,2008.0,,tertiary,2009.0,,isolates,highly_important,,,,amr_prevalence,,,,,,,4,hospital,,,,,,Dinda2013-Kenya-AKUHNairobi-20082009-1,,Escherichia coli
3,,,Kenya,,,,amr_prevalence,,amoxicillin-clavulanate,2008.0,,tertiary,2009.0,,isolates,highly_important,,,,amr_prevalence,,,,,,,4,hospital,,,,,,Dinda2013-Kenya-AKUHNairobi-20082009-1,,Escherichia coli
1,,,Kenya,,,,amr_prevalence,,cefotaxime,2008.0,,tertiary,2009.0,,isolates,critically_important,,,,amr_prevalence,,,,,,,4,hospital,,,,,,Dinda2013-Kenya-AKUHNairobi-20082009-1,,Escherichia coli
2,,,Kenya,,,,amr_prevalence,,chloramphenicol,2008.0,,tertiary,2009.0,,isolates,highly_important,,,,amr_prevalence,,,,,,,4,hospital,,,,,,Dinda2013-Kenya-AKUHNairobi-20082009-1,,Escherichia coli
2,,,Kenya,,,,amr_prevalence,,cefuroxime,2008.0,,tertiary,2009.0,,isolates,highly_important,,,,amr_prevalence,,,,,,,4,hospital,,,,,,Dinda2013-Kenya-AKUHNairobi-20082009-1,,Escherichia coli
2,,,Kenya,,,,amr_prevalence,,ciprofloxacin,2008.0,,tertiary,2009.0,,isolates,critically_important,,,,amr_prevalence,,,,,,,4,hospital,,,,,,Dinda2013-Kenya-AKUHNairobi-20082009-1,,Escherichia coli
2,,,Kenya,,,,amr_prevalence,,gentamicin,2008.0,,tertiary,2009.0,,isolates,highly_important,,,,amr_prevalence,,,,,,,4,hospital,,,,,,Dinda2013-Kenya-AKUHNairobi-20082009-1,,Escherichia coli
2,,,Kenya,,,,amr_prevalence,,co-trimoxazole,2008.0,,tertiary,2009.0,,isolates,highly_important,,,,amr_prevalence,,,,,,,3,hospital,,,,,,Dinda2013-Kenya-AKUHNairobi-20082009-1,,Klebsiella spp.
1,,,Kenya,,,,amr_prevalence,,doxycycline,2008.0,,tertiary,2009.0,,isolates,highly_important,,,,amr_prevalence,,,,,,,3,hospital,,,,,,Dinda2013-Kenya-AKUHNairobi-20082009-1,,Klebsiella spp.
2,,,Kenya,,,,amr_prevalence,,amoxicillin-clavulanate,2008.0,,tertiary,2009.0,,isolates,highly_important,,,,amr_prevalence,,,,,,,3,hospital,,,,,,Dinda2013-Kenya-AKUHNairobi-20082009-1,,Klebsiella spp.
2,,,Kenya,,,,amr_prevalence,,cefotaxime,2008.0,,tertiary,2009.0,,isolates,critically_important,,,,amr_prevalence,,,,,,,3,hospital,,,,,,Dinda2013-Kenya-AKUHNairobi-20082009-1,,Klebsiella spp.
1,,,Kenya,,,,amr_prevalence,,chloramphenicol,2008.0,,tertiary,2009.0,,isolates,highly_important,,,,amr_prevalence,,,,,,,3,hospital,,,,,,Dinda2013-Kenya-AKUHNairobi-20082009-1,,Klebsiella spp.
0,,,Kenya,,,,amr_prevalence,,cefuroxime,2008.0,,tertiary,2009.0,,isolates,highly_important,,,,amr_prevalence,,,,,,,3,hospital,,,,,,Dinda2013-Kenya-AKUHNairobi-20082009-1,,Klebsiella spp.
0,,,Kenya,,,,amr_prevalence,,ciprofloxacin,2008.0,,tertiary,2009.0,,isolates,critically_important,,,,amr_prevalence,,,,,,,3,hospital,,,,,,Dinda2013-Kenya-AKUHNairobi-20082009-1,,Klebsiella spp.
2,,,Kenya,,,,amr_prevalence,,gentamicin,2008.0,,tertiary,2009.0,,isolates,highly_important,,,,amr_prevalence,,,,,,,3,hospital,,,,,,Dinda2013-Kenya-AKUHNairobi-20082009-1,,Klebsiella spp.
3,,,Kenya,,,,amr_prevalence,,ciprofloxacin,2008.0,,tertiary,2009.0,,isolates,critically_important,,,,amr_prevalence,,,,,,,4,hospital,,,,,,Dinda2013-Kenya-AKUHNairobi-20082009-1,,Pseudomonas aeruginosa
2,,,Kenya,,,,amr_prevalence,,gentamicin,2008.0,,tertiary,2009.0,,isolates,highly_important,,,,amr_prevalence,,,,,,,4,hospital,,,,,,Dinda2013-Kenya-AKUHNairobi-20082009-1,,Pseudomonas aeruginosa
3,,,Kenya,,,,amr_prevalence,,piperacillin-tazobactam,2008.0,,tertiary,2009.0,,isolates,critically_important,,,,amr_prevalence,,,,,,,4,hospital,,,,,,Dinda2013-Kenya-AKUHNairobi-20082009-1,,Pseudomonas aeruginosa
2,,,Kenya,,,,amr_prevalence,,cefepime,2008.0,,tertiary,2009.0,,isolates,critically_important,,,,amr_prevalence,,,,,,,4,hospital,,,,,,Dinda2013-Kenya-AKUHNairobi-20082009-1,,Pseudomonas aeruginosa
2,,,Kenya,,,,amr_prevalence,,ceftazidime,2008.0,,tertiary,2009.0,,isolates,critically_important,,,,amr_prevalence,,,,,,,4,hospital,,,,,,Dinda2013-Kenya-AKUHNairobi-20082009-1,,Pseudomonas aeruginosa
2,,,Kenya,,,,amr_prevalence,,imipenem,2008.0,,tertiary,2009.0,,isolates,critically_important,,,,amr_prevalence,,,,,,,4,hospital,,,,,,Dinda2013-Kenya-AKUHNairobi-20082009-1,,Pseudomonas aeruginosa
2,,,Kenya,,,,amr_prevalence,,piperacillin,2008.0,,tertiary,2009.0,,isolates,highly_important,,,,amr_prevalence,,,,,,,4,hospital,,,,,,Dinda2013-Kenya-AKUHNairobi-20082009-1,,Pseudomonas aeruginosa
1,,,Kenya,,,,amr_prevalence,,ceftriaxone,2008.0,,tertiary,2009.0,,isolates,critically_important,,,,amr_prevalence,,,,,,,4,hospital,,,,,,Dinda2013-Kenya-AKUHNairobi-20082009-1,,Pseudomonas aeruginosa
20,disk_diffusion,,Eritrea,,,,amr_prevalence,CLSI,penicillin,2017.0,,tertiary,2017.0,,isolates,important,CLSI 2017 (M100-S25),,,amr_prevalence,17.0,wound_swab,,,disk diffusion (oxacillin disk),,20,hospital,,,,,mm,Garoy2021-Eritrea-AsmaraHospitals-2017-01,MDR: nonsusceptibility to at least one agent in ≥3 antimicrobial drug classes.,Staphylococcus aureus
14,disk_diffusion,,Eritrea,,,,amr_prevalence,CLSI,oxacillin,2017.0,,tertiary,2017.0,,isolates,important,CLSI 2017 (M100-S25),,,amr_prevalence,17.0,wound_swab,,,disk diffusion (oxacillin disk),,20,hospital,,,,,mm,Garoy2021-Eritrea-AsmaraHospitals-2017-01,MDR: nonsusceptibility to at least one agent in ≥3 antimicrobial drug classes.,Staphylococcus aureus
12,disk_diffusion,,Eritrea,,,,amr_prevalence,CLSI,vancomycin,2017.0,,tertiary,2017.0,,isolates,critically_important,CLSI 2017 (M100-S25),,,amr_prevalence,17.0,wound_swab,,,disk diffusion (oxacillin disk),,20,hospital,,,,,mm,Garoy2021-Eritrea-AsmaraHospitals-2017-01,MDR: nonsusceptibility to at least one agent in ≥3 antimicrobial drug classes.,Staphylococcus aureus
5,disk_diffusion,,Eritrea,,,,amr_prevalence,CLSI,clindamycin,2017.0,,tertiary,2017.0,,isolates,critically_important,CLSI 2017 (M100-S25),,,amr_prevalence,17.0,wound_swab,,,disk diffusion (oxacillin disk); D-test for inducible resistance,,20,hospital,,,,,mm,Garoy2021-Eritrea-AsmaraHospitals-2017-01,MDR: nonsusceptibility to at least one agent in ≥3 antimicrobial drug classes.,Staphylococcus aureus
5,disk_diffusion,,Eritrea,,,,amr_prevalence,CLSI,erythromycin,2017.0,,tertiary,2017.0,,isolates,important,CLSI 2017 (M100-S25),,,amr_prevalence,17.0,wound_swab,,,disk diffusion (oxacillin disk); D-test for inducible resistance,,20,hospital,,,,,mm,Garoy2021-Eritrea-AsmaraHospitals-2017-01,MDR: nonsusceptibility to at least one agent in ≥3 antimicrobial drug classes.,Staphylococcus aureus
10,disk_diffusion,,Eritrea,,,,amr_prevalence,CLSI,ampicillin,2017.0,,tertiary,2017.0,,isolates,critically_important,CLSI 2017 (M100-S25),,,amr_prevalence,10.0,wound_swab,,,,,10,hospital,,,,,mm,Garoy2021-Eritrea-AsmaraHospitals-2017-01,MDR: nonsusceptibility to at least one agent in ≥3 antimicrobial drug classes.,Escherichia coli
9,disk_diffusion,,Eritrea,,,,amr_prevalence,CLSI,trimethoprim-sulfamethoxazole,2017.0,,tertiary,2017.0,,isolates,critically_important,CLSI 2017 (M100-S25),,,amr_prevalence,10.0,wound_swab,,,,,10,hospital,,,,,mm,Garoy2021-Eritrea-AsmaraHospitals-2017-01,MDR: nonsusceptibility to at least one agent in ≥3 antimicrobial drug classes.,Escherichia coli
7,disk_diffusion,,Eritrea,,,,amr_prevalence,CLSI,gentamicin,2017.0,,tertiary,2017.0,,isolates,critically_important,CLSI 2017 (M100-S25),,,amr_prevalence,10.0,wound_swab,,,,,10,hospital,,,,,mm,Garoy2021-Eritrea-AsmaraHospitals-2017-01,MDR: nonsusceptibility to at least one agent in ≥3 antimicrobial drug classes.,Escherichia coli
9,disk_diffusion,,Eritrea,,,,amr_prevalence,CLSI,ceftazidime,2017.0,,tertiary,2017.0,,isolates,critically_important,CLSI 2017 (M100-S25),,,amr_prevalence,10.0,wound_swab,,,,,10,hospital,,,,,mm,Garoy2021-Eritrea-AsmaraHospitals-2017-01,MDR: nonsusceptibility to at least one agent in ≥3 antimicrobial drug classes.,Escherichia coli
8,disk_diffusion,,Eritrea,,,,amr_prevalence,CLSI,ceftriaxone,2017.0,,tertiary,2017.0,,isolates,critically_important,CLSI 2017 (M100-S25),,,amr_prevalence,10.0,wound_swab,,,,,10,hospital,,,,,mm,Garoy2021-Eritrea-AsmaraHospitals-2017-01,MDR: nonsusceptibility to at least one agent in ≥3 antimicrobial drug classes.,Escherichia coli
34,disk_diffusion,,Tanzania,,,,amr_prevalence,EUCAST,oxacillin,2013.0,,tertiary,2013.0,,isolates,highly_important,2013/2014,,,amr_prevalence,,wound_swab,,,oxacillin disc diffusion,,43,hospital,,,,,,Gentilotti2020-Tanzania-Dodoma-2013-2015-1,,Staphylococcus aureus
3,disk_diffusion,,Tanzania,,,,amr_prevalence,EUCAST,oxacillin,2015.0,,tertiary,2015.0,,isolates,highly_important,2013/2014,,,amr_prevalence,,wound_swab,,,oxacillin disc diffusion,,14,hospital,,,,,,Gentilotti2020-Tanzania-Dodoma-2013-2015-1,,Staphylococcus aureus
4,disk_diffusion,,Tanzania,,,,amr_prevalence,EUCAST,multiple_classes,2013.0,,tertiary,2013.0,,isolates,,2013/2014,,,amr_prevalence,4.0,wound_swab,,,,,4,hospital,,,,,,Gentilotti2020-Tanzania-Dodoma-2013-2015-1,"Resistances to amoxicillin/clavulanate, ceftriaxone (or ceftazidime), and/or gentamycin, and/or ciprofloxacin.",Klebsiella spp.
3,disk_diffusion,,Tanzania,,,,amr_prevalence,EUCAST,multiple_classes,2015.0,,tertiary,2015.0,,isolates,,2013/2014,,,amr_prevalence,3.0,wound_swab,,,,,7,hospital,,,,,,Gentilotti2020-Tanzania-Dodoma-2013-2015-1,"Resistances to amoxicillin/clavulanate, ceftriaxone (or ceftazidime), and/or gentamycin, and/or ciprofloxacin.",Klebsiella spp.
10,disk_diffusion,,Tanzania,,,,amr_prevalence,CLSI,ampicillin,2024.0,,tertiary,2024.0,,isolates,critically_important,,,,amr_prevalence,,wound_swab,,,,,11,hospital,,,,,mm,Hamudu2025-Tanzania-BMC_SRHH-2024-01,Multi drug resistance phenotype reported.,Escherichia coli
4,disk_diffusion,,Tanzania,,,,amr_prevalence,CLSI,ceftriaxone,2024.0,,tertiary,2024.0,,isolates,critically_important,,,,amr_prevalence,,wound_swab,,,,,7,hospital,,,,,mm,Hamudu2025-Tanzania-BMC_SRHH-2024-01,Multi drug resistance phenotype reported.,Staphylococcus aureus
1,disk_diffusion,,Tanzania,,,,amr_prevalence,CLSI,ceftazidime,2024.0,,tertiary,2024.0,,isolates,critically_important,,,,amr_prevalence,,wound_swab,,,,,4,hospital,,,,,mm,Hamudu2025-Tanzania-BMC_SRHH-2024-01,Multi drug resistance phenotype reported.,Pseudomonas aeruginosa
1,disk_diffusion,,Tanzania,,,,amr_prevalence,CLSI,ampicillin,2024.0,,tertiary,2024.0,,isolates,important,,,,amr_prevalence,,wound_swab,,,,,3,hospital,,,,,mm,Hamudu2025-Tanzania-BMC_SRHH-2024-01,Multi drug resistance phenotype reported.,Enterococcus faecalis
20,disk_diffusion,,Uganda,,,,amr_prevalence,CLSI,ampicillin,2015.0,,tertiary,2015.0,,isolates,important,CLSI 2012,,,amr_prevalence,18.0,wound_swab,,,Oxacillin disk diffusion,,20,hospital,,,,,mm,Hope2019-Uganda-Mbarara-2015-01,Resistance to three or more antibiotics tested.,Staphylococcus aureus
20,disk_diffusion,,Uganda,,,,amr_prevalence,CLSI,oxacillin,2015.0,,tertiary,2015.0,,isolates,important,CLSI 2012,,,amr_prevalence,18.0,wound_swab,,,Oxacillin disk diffusion,,20,hospital,,,,,mm,Hope2019-Uganda-Mbarara-2015-01,Resistance to three or more antibiotics tested.,Staphylococcus aureus
27,disk_diffusion,,Uganda,,,,amr_prevalence,CLSI,ampicillin,2015.0,,tertiary,2015.0,,isolates,important,CLSI 2012,,,amr_prevalence,27.0,wound_swab,,,,,27,hospital,,,,,mm,Hope2019-Uganda-Mbarara-2015-01,Resistance to three or more antibiotics tested.,Klebsiella spp.
23,disk_diffusion,,Uganda,,,,amr_prevalence,CLSI,ceftriaxone,2015.0,,tertiary,2015.0,,isolates,critically_important,CLSI 2012,,,amr_prevalence,27.0,wound_swab,,,,,27,hospital,,,,,mm,Hope2019-Uganda-Mbarara-2015-01,Resistance to three or more antibiotics tested.,Klebsiella spp.
9,disk_diffusion,,Uganda,,,,amr_prevalence,CLSI,ampicillin,2015.0,,tertiary,2015.0,,isolates,important,CLSI 2012,,,amr_prevalence,9.0,wound_swab,,,,,9,hospital,,,,,mm,Hope2019-Uganda-Mbarara-2015-01,Resistance to three or more antibiotics tested.,Escherichia coli
9,disk_diffusion,,Uganda,,,,amr_prevalence,CLSI,ceftriaxone,2015.0,,tertiary,2015.0,,isolates,critically_important,CLSI 2012,,,amr_prevalence,9.0,wound_swab,,,,,9,hospital,,,,,mm,Hope2019-Uganda-Mbarara-2015-01,Resistance to three or more antibiotics tested.,Escherichia coli
58,disk_diffusion,,Democratic Republic of Congo,,,,amr_prevalence,CLSI,ampicillin,2013.0,,tertiary,2013.0,,isolates,important,CLSI 2011,,,amr_prevalence,,wound_swab,,,disk diffusion using oxacillin (1 µg) on Mueller Hinton agar with 4% NaCl,,74,hospital,,,,,mm,Iyamba2014-DRC-Kinshasa-2013-01,Multidrug resistance was observed in MRSA and MR-CNS strains.,Staphylococcus aureus
9,disk_diffusion,,Democratic Republic of Congo,,,,amr_prevalence,CLSI,amoxicillin-clavulanate,2013.0,,tertiary,2013.0,,isolates,critically_important,CLSI 2011,,,amr_prevalence,,wound_swab,,,disk diffusion using oxacillin (1 µg) on Mueller Hinton agar with 4% NaCl,,74,hospital,,,,,mm,Iyamba2014-DRC-Kinshasa-2013-01,Multidrug resistance was observed in MRSA and MR-CNS strains.,Staphylococcus aureus
37,disk_diffusion,,Democratic Republic of Congo,,,,amr_prevalence,CLSI,ceftazidime,2013.0,,tertiary,2013.0,,isolates,critically_important,CLSI 2011,,,amr_prevalence,,wound_swab,,,disk diffusion using oxacillin (1 µg) on Mueller Hinton agar with 4% NaCl,,74,hospital,,,,,mm,Iyamba2014-DRC-Kinshasa-2013-01,Multidrug resistance was observed in MRSA and MR-CNS strains.,Staphylococcus aureus
30,disk_diffusion,,Democratic Republic of Congo,,,,amr_prevalence,CLSI,cefotaxime,2013.0,,tertiary,2013.0,,isolates,critically_important,CLSI 2011,,,amr_prevalence,,wound_swab,,,disk diffusion using oxacillin (1 µg) on Mueller Hinton agar with 4% NaCl,,74,hospital,,,,,mm,Iyamba2014-DRC-Kinshasa-2013-01,Multidrug resistance was observed in MRSA and MR-CNS strains.,Staphylococcus aureus
50,disk_diffusion,,Democratic Republic of Congo,,,,amr_prevalence,CLSI,ciprofloxacin,2013.0,,tertiary,2013.0,,isolates,critically_important,CLSI 2011,,,amr_prevalence,,wound_swab,,,disk diffusion using oxacillin (1 µg) on Mueller Hinton agar with 4% NaCl,,74,hospital,,,,,mm,Iyamba2014-DRC-Kinshasa-2013-01,Multidrug resistance was observed in MRSA and MR-CNS strains.,Staphylococcus aureus
52,disk_diffusion,,Democratic Republic of Congo,,,,amr_prevalence,CLSI,clindamycin,2013.0,,tertiary,2013.0,,isolates,critically_important,CLSI 2011,,,amr_prevalence,,wound_swab,,,disk diffusion using oxacillin (1 µg) on Mueller Hinton agar with 4% NaCl,,74,hospital,,,,,mm,Iyamba2014-DRC-Kinshasa-2013-01,Multidrug resistance was observed in MRSA and MR-CNS strains.,Staphylococcus aureus
54,disk_diffusion,,Democratic Republic of Congo,,,,amr_prevalence,CLSI,cotrimoxazole,2013.0,,tertiary,2013.0,,isolates,critically_important,CLSI 2011,,,amr_prevalence,,wound_swab,,,disk diffusion using oxacillin (1 µg) on Mueller Hinton agar with 4% NaCl,,74,hospital,,,,,mm,Iyamba2014-DRC-Kinshasa-2013-01,Multidrug resistance was observed in MRSA and MR-CNS strains.,Staphylococcus aureus
51,disk_diffusion,,Democratic Republic of Congo,,,,amr_prevalence,CLSI,erythromycin,2013.0,,tertiary,2013.0,,isolates,critically_important,CLSI 2011,,,amr_prevalence,,wound_swab,,,disk diffusion using oxacillin (1 µg) on Mueller Hinton agar with 4% NaCl,,74,hospital,,,,,mm,Iyamba2014-DRC-Kinshasa-2013-01,Multidrug resistance was observed in MRSA and MR-CNS strains.,Staphylococcus aureus
0,disk_diffusion,,Democratic Republic of Congo,,,,amr_prevalence,CLSI,imipenem,2013.0,,tertiary,2013.0,,isolates,critically_important,CLSI 2011,,,amr_prevalence,,wound_swab,,,disk diffusion using oxacillin (1 µg) on Mueller Hinton agar with 4% NaCl,,74,hospital,,,,,mm,Iyamba2014-DRC-Kinshasa-2013-01,Multidrug resistance was observed in MRSA and MR-CNS strains.,Staphylococcus aureus
11,disk_diffusion,,Democratic Republic of Congo,,,,amr_prevalence,CLSI,vancomycin,2013.0,,tertiary,2013.0,,isolates,critically_important,CLSI 2011,,,amr_prevalence,,wound_swab,,,disk diffusion using oxacillin (1 µg) on Mueller Hinton agar with 4% NaCl,,74,hospital,,,,,mm,Iyamba2014-DRC-Kinshasa-2013-01,Multidrug resistance was observed in MRSA and MR-CNS strains.,Staphylococcus aureus
1,disk_diffusion,,Malawi,,,,amr_prevalence,unspecified,ceftriaxone,2023.0,,tertiary,2023.0,,isolates,critically_important,,,,amr_prevalence,,wound_swab,,,,,1,hospital,,,,,,Kachipedzu2024-Malawi-QECH-2023-1,,Acinetobacter baumannii
1,disk_diffusion,,Malawi,,,,amr_prevalence,unspecified,ciprofloxacin,2023.0,,tertiary,2023.0,,isolates,critically_important,,,,amr_prevalence,,wound_swab,,,,,1,hospital,,,,,,Kachipedzu2024-Malawi-QECH-2023-1,,Acinetobacter baumannii
0,disk_diffusion,,Malawi,,,,amr_prevalence,unspecified,gentamicin,2023.0,,tertiary,2023.0,,isolates,highly_important,,,,amr_prevalence,,wound_swab,,,,,1,hospital,,,,,,Kachipedzu2024-Malawi-QECH-2023-1,,Acinetobacter baumannii
1,disk_diffusion,,Malawi,,,,amr_prevalence,unspecified,cefotaxime,2023.0,,tertiary,2023.0,,isolates,critically_important,,,,amr_prevalence,,wound_swab,,,,,1,hospital,,,,,,Kachipedzu2024-Malawi-QECH-2023-1,,Acinetobacter baumannii
1,disk_diffusion,,Malawi,,,,amr_prevalence,unspecified,tigecycline,2023.0,,tertiary,2023.0,,isolates,highly_important,,,,amr_prevalence,,wound_swab,,,,,1,hospital,,,,,,Kachipedzu2024-Malawi-QECH-2023-1,,Acinetobacter baumannii
1,disk_diffusion,,Malawi,,,,amr_prevalence,unspecified,chloramphenicol,2023.0,,tertiary,2023.0,,isolates,highly_important,,,,amr_prevalence,,wound_swab,,,,,1,hospital,,,,,,Kachipedzu2024-Malawi-QECH-2023-1,,Enterobacteriaceae
0,disk_diffusion,,Malawi,,,,amr_prevalence,unspecified,ciprofloxacin,2023.0,,tertiary,2023.0,,isolates,critically_important,,,,amr_prevalence,,wound_swab,,,,,1,hospital,,,,,,Kachipedzu2024-Malawi-QECH-2023-1,,Enterobacteriaceae
1,disk_diffusion,,Malawi,,,,amr_prevalence,unspecified,co-trimoxazole,2023.0,,tertiary,2023.0,,isolates,highly_important,,,,amr_prevalence,,wound_swab,,,,,1,hospital,,,,,,Kachipedzu2024-Malawi-QECH-2023-1,,Enterobacteriaceae
0,disk_diffusion,,Malawi,,,,amr_prevalence,unspecified,gentamicin,2023.0,,tertiary,2023.0,,isolates,highly_important,,,,amr_prevalence,,wound_swab,,,,,1,hospital,,,,,,Kachipedzu2024-Malawi-QECH-2023-1,,Enterobacteriaceae
0,disk_diffusion,,Malawi,,,,amr_prevalence,unspecified,meropenem,2023.0,,tertiary,2023.0,,isolates,critically_important,,,,amr_prevalence,,wound_swab,,,,,1,hospital,,,,,,Kachipedzu2024-Malawi-QECH-2023-1,,Enterobacteriaceae
0,disk_diffusion,,Malawi,,,,amr_prevalence,unspecified,amikacin,2023.0,,tertiary,2023.0,,isolates,highly_important,,,,amr_prevalence,,wound_swab,,,,,1,hospital,,,,,,Kachipedzu2024-Malawi-QECH-2023-1,,Enterobacteriaceae
0,disk_diffusion,,Malawi,,,,amr_prevalence,unspecified,tigecycline,2023.0,,tertiary,2023.0,,isolates,highly_important,,,,amr_prevalence,,wound_swab,,,,,1,hospital,,,,,,Kachipedzu2024-Malawi-QECH-2023-1,,Enterobacteriaceae
3,disk_diffusion,,Malawi,,,,amr_prevalence,unspecified,clindamycin,2023.0,,tertiary,2023.0,,isolates,highly_important,,,,amr_prevalence,,wound_swab,,,,,3,hospital,,,,,,Kachipedzu2024-Malawi-QECH-2023-1,,Staphylococcus aureus
3,disk_diffusion,,Malawi,,,,amr_prevalence,unspecified,erythromycin,2023.0,,tertiary,2023.0,,isolates,highly_important,,,,amr_prevalence,,wound_swab,,,,,3,hospital,,,,,,Kachipedzu2024-Malawi-QECH-2023-1,,Staphylococcus aureus
3,disk_diffusion,,Malawi,,,,amr_prevalence,unspecified,gentamicin,2023.0,,tertiary,2023.0,,isolates,highly_important,,,,amr_prevalence,,wound_swab,,,,,3,hospital,,,,,,Kachipedzu2024-Malawi-QECH-2023-1,,Staphylococcus aureus
3,disk_diffusion,,Malawi,,,,amr_prevalence,unspecified,cefoxitin,2023.0,,tertiary,2023.0,,isolates,highly_important,,,,amr_prevalence,,wound_swab,,,Cefoxitin screen suggests MRSA.,,3,hospital,,,,,,Kachipedzu2024-Malawi-QECH-2023-1,,Staphylococcus aureus
0,disk_diffusion,,Cameroon,,,,amr_prevalence,CLSI,ofloxacin,2010.0,,mixed,2011.0,,isolates,critically_important,CLSI 2009,,,amr_prevalence,,wound_swab,,,,,48,hospital,,,,,mm,Akoachere2014-Cameroon-Buea-201010201103-01,Resistance to at least two drugs (excluding oxacillin),Staphylococcus aureus
48,disk_diffusion,,Cameroon,,,,amr_prevalence,CLSI,oxacillin,2010.0,,mixed,2011.0,,isolates,critically_important,CLSI 2009,,,amr_prevalence,,wound_swab,,,,,48,hospital,,,,,mm,Akoachere2014-Cameroon-Buea-201010201103-01,Resistance to at least two drugs (excluding oxacillin),Staphylococcus aureus
6,disk_diffusion,,Cameroon,,,,amr_prevalence,CLSI,gentamicin,2010.0,,mixed,2011.0,,isolates,critically_important,CLSI 2009,,,amr_prevalence,,wound_swab,,,,,48,hospital,,,,,mm,Akoachere2014-Cameroon-Buea-201010201103-01,Resistance to at least two drugs (excluding oxacillin),Staphylococcus aureus
0,disk_diffusion,,Cameroon,,,,amr_prevalence,CLSI,ofloxacin,2010.0,,mixed,2011.0,,isolates,critically_important,CLSI 2009,,,amr_prevalence,,wound_swab,,,,,39,hospital,,,,,mm,Akoachere2014-Cameroon-Buea-201010201103-01,Resistance to at least two drugs (excluding oxacillin),Pseudomonas aeruginosa
10,disk_diffusion,,Cameroon,,,,amr_prevalence,CLSI,gentamicin,2010.0,,mixed,2011.0,,isolates,critically_important,CLSI 2009,,,amr_prevalence,,wound_swab,,,,,39,hospital,,,,,mm,Akoachere2014-Cameroon-Buea-201010201103-01,Resistance to at least two drugs (excluding oxacillin),Pseudomonas aeruginosa
0,disk_diffusion,,Cameroon,,,,amr_prevalence,CLSI,ofloxacin,2010.0,,mixed,2011.0,,isolates,critically_important,CLSI 2009,,,amr_prevalence,,wound_swab,,,,,22,hospital,,,,,mm,Akoachere2014-Cameroon-Buea-201010201103-01,Resistance to at least two drugs (excluding oxacillin),Klebsiella pneumoniae
21,disk_diffusion,,Tanzania,,,,amr_prevalence,CLSI,ampicillin,2013.0,,tertiary,2015.0,,isolates,important,CLSI 2013,,,amr_prevalence,,wound_swab,,,,,28,hospital,,,,,mm,Kumburu2017-Tanzania-KCMC-2013-2015-01,,Proteus spp.
23,disk_diffusion,,Tanzania,,,,amr_prevalence,CLSI,cefazolin,2013.0,,tertiary,2015.0,,isolates,important,CLSI 2013,,,amr_prevalence,,wound_swab,,,,,28,hospital,,,,,mm,Kumburu2017-Tanzania-KCMC-2013-2015-01,,Proteus spp.
24,disk_diffusion,,Tanzania,,,,amr_prevalence,CLSI,ampicillin,2013.0,,tertiary,2015.0,,isolates,important,CLSI 2013,,,amr_prevalence,,wound_swab,,,,,26,hospital,,,,,mm,Kumburu2017-Tanzania-KCMC-2013-2015-01,,Klebsiella spp.
13,disk_diffusion,,Tanzania,,,,amr_prevalence,CLSI,ampicillin,2013.0,,tertiary,2015.0,,isolates,important,CLSI 2013,,,amr_prevalence,,wound_swab,,,,,19,hospital,,,,,mm,Kumburu2017-Tanzania-KCMC-2013-2015-01,,Escherichia coli
22,disk_diffusion,,Tanzania,,,,amr_prevalence,CLSI,penicillin,2013.0,,tertiary,2015.0,,isolates,important,CLSI 2013,,,amr_prevalence,,wound_swab,,,Cefoxitin disk diffusion,,22,hospital,,,,,mm,Kumburu2017-Tanzania-KCMC-2013-2015-01,,Staphylococcus aureus
6,disk_diffusion,,Tanzania,,,,amr_prevalence,CLSI,cefoxitin,2013.0,,tertiary,2015.0,,isolates,important,CLSI 2013,,,amr_prevalence,,wound_swab,,,Cefoxitin disk diffusion,,22,hospital,,,,,mm,Kumburu2017-Tanzania-KCMC-2013-2015-01,,Staphylococcus aureus
43,disk_diffusion,,Uganda,,disk diffusion (cephalosporin/clavulanic acid combination),,amr_prevalence,CLSI,ceftriaxone,2021.0,,tertiary,2022.0,,isolates,critically_important,CLSI 2020,,,amr_prevalence,,wound_swab,,,,,45,hospital,,,,,mm,Jung2023-Uganda-Mulago-2021Q4_2022Q1-01,,Escherichia coli
22,disk_diffusion,,Uganda,,disk diffusion (cephalosporin/clavulanic acid combination),,amr_prevalence,CLSI,gentamicin,2021.0,,tertiary,2022.0,,isolates,critically_important,CLSI 2020,,,amr_prevalence,,wound_swab,,,,,40,hospital,,,,,mm,Jung2023-Uganda-Mulago-2021Q4_2022Q1-01,,Escherichia coli
32,disk_diffusion,,Uganda,,,,amr_prevalence,CLSI,gentamicin,2021.0,,tertiary,2022.0,,isolates,critically_important,CLSI 2020,,,amr_prevalence,,wound_swab,,,,,39,hospital,,,,,mm,Jung2023-Uganda-Mulago-2021Q4_2022Q1-01,,Acinetobacter spp.
30,disk_diffusion,,Uganda,,,,amr_prevalence,CLSI,ceftriaxone,2021.0,,tertiary,2022.0,,isolates,critically_important,CLSI 2020,,,amr_prevalence,,wound_swab,,,,,32,hospital,,,,,mm,Jung2023-Uganda-Mulago-2021Q4_2022Q1-01,,Klebsiella spp.
11,disk_diffusion,,Uganda,,,,amr_prevalence,CLSI,gentamicin,2021.0,,tertiary,2022.0,,isolates,critically_important,CLSI 2020,,,amr_prevalence,,wound_swab,,,,,24,hospital,,,,,mm,Jung2023-Uganda-Mulago-2021Q4_2022Q1-01,,Pseudomonas aeruginosa
17,disk_diffusion,,Uganda,,,,amr_prevalence,CLSI,vancomycin,2021.0,,tertiary,2022.0,,isolates,critically_important,CLSI 2020,,,amr_prevalence,,wound_swab,,,,,20,hospital,,,,,mm,Jung2023-Uganda-Mulago-2021Q4_2022Q1-01,,Enterococcus spp.
4,disk_diffusion,,Uganda,,,,amr_prevalence,CLSI,methicillin,2021.0,,tertiary,2022.0,,isolates,critically_important,CLSI 2020,,,amr_prevalence,,wound_swab,,,,,19,hospital,,,,,mm,Jung2023-Uganda-Mulago-2021Q4_2022Q1-01,,Staphylococcus aureus
13,disk_diffusion,,Tanzania,12.0,Double disc approximation method,,amr_prevalence,CLSI,ampicillin,2011.0,,tertiary,2012.0,,isolates,critically_important,CLSI 2010,,,amr_prevalence,13.0,wound_swab,,,,,13,hospital,,,,,mm,Manyahi2014-Tanzania-Muhimbili-2011-2012-1,MDR defined as acquired non-susceptibility to at least one agent in three or more antimicrobial categories.,Escherichia coli
12,disk_diffusion,,Tanzania,12.0,Double disc approximation method,,amr_prevalence,CLSI,amoxicillin-clavulanate,2011.0,,tertiary,2012.0,,isolates,critically_important,CLSI 2010,,,amr_prevalence,13.0,wound_swab,,,,,13,hospital,,,,,mm,Manyahi2014-Tanzania-Muhimbili-2011-2012-1,MDR defined as acquired non-susceptibility to at least one agent in three or more antimicrobial categories.,Escherichia coli
12,disk_diffusion,,Tanzania,12.0,Double disc approximation method,,amr_prevalence,CLSI,ceftriaxone,2011.0,,tertiary,2012.0,,isolates,critically_important,CLSI 2010,,,amr_prevalence,13.0,wound_swab,,,,,13,hospital,,,,,mm,Manyahi2014-Tanzania-Muhimbili-2011-2012-1,MDR defined as acquired non-susceptibility to at least one agent in three or more antimicrobial categories.,Escherichia coli
15,disk_diffusion,,Tanzania,,,,amr_prevalence,CLSI,penicillin,2011.0,,tertiary,2012.0,,isolates,critically_important,CLSI 2010,,,amr_prevalence,8.0,wound_swab,,,Cefoxitin disc diffusion (zone ≤21 mm),,18,hospital,,,,,mm,Manyahi2014-Tanzania-Muhimbili-2011-2012-1,MDR defined as acquired non-susceptibility to at least one agent in three or more antimicrobial categories.,Staphylococcus aureus
16,disk_diffusion,,Tanzania,11.0,Double disc approximation method,,amr_prevalence,CLSI,ampicillin,2011.0,,tertiary,2012.0,,isolates,critically_important,CLSI 2010,,,amr_prevalence,14.0,wound_swab,,,,,16,hospital,,,,,mm,Manyahi2014-Tanzania-Muhimbili-2011-2012-1,MDR defined as acquired non-susceptibility to at least one agent in three or more antimicrobial categories.,Klebsiella pneumoniae
4,disk_diffusion,,Ethiopia,,,,amr_prevalence,CLSI,gentamicin,2012.0,,tertiary,2012.0,,isolates,critically_important,CLSI 2011,,,amr_prevalence,,wound_swab,,,,,40,hospital,,,,,mm,Mengesha2014-Ethiopia-Ayder-2012-1,,Staphylococcus aureus
0,disk_diffusion,,Ethiopia,,,,amr_prevalence,CLSI,vancomycin,2012.0,,tertiary,2012.0,,isolates,critically_important,CLSI 2011,,,amr_prevalence,,wound_swab,,,,,40,hospital,,,,,mm,Mengesha2014-Ethiopia-Ayder-2012-1,,Staphylococcus aureus
8,disk_diffusion,,Ethiopia,,,,amr_prevalence,CLSI,gentamicin,2012.0,,tertiary,2012.0,,isolates,critically_important,CLSI 2011,,,amr_prevalence,,wound_swab,,,,,29,hospital,,,,,mm,Mengesha2014-Ethiopia-Ayder-2012-1,,Klebsiella spp.
0,disk_diffusion,,Ethiopia,,,,amr_prevalence,CLSI,gentamicin,2012.0,,tertiary,2012.0,,isolates,critically_important,CLSI 2011,,,amr_prevalence,,wound_swab,,,,,11,hospital,,,,,mm,Mengesha2014-Ethiopia-Ayder-2012-1,,Pseudomonas aeruginosa
0,disk_diffusion,,Ethiopia,,,,amr_prevalence,CLSI,vancomycin,2012.0,,tertiary,2012.0,,isolates,critically_important,CLSI 2011,,,amr_prevalence,,wound_swab,,,,,18,hospital,,,,,mm,Mengesha2014-Ethiopia-Ayder-2012-1,,Coagulase-negative staphylococci
11,disk_diffusion,,Ethiopia,,,,amr_prevalence,CLSI,gentamicin,2012.0,,tertiary,2012.0,,isolates,critically_important,CLSI 2011,,,amr_prevalence,,wound_swab,,,,,65,hospital,,,,,mm,Mengesha2014-Ethiopia-Ayder-2012-1,,Gram-negative bacteria (aggregate)
0,disk_diffusion,,Ethiopia,,,,amr_prevalence,CLSI,vancomycin,2012.0,,tertiary,2012.0,,isolates,critically_important,CLSI 2011,,,amr_prevalence,,wound_swab,,,,,58,hospital,,,,,mm,Mengesha2014-Ethiopia-Ayder-2012-1,,Gram-positive bacteria (aggregate)
3,disk_diffusion,,Ethiopia,,,,amr_prevalence,CLSI,penicillin,2019.0,,tertiary,2019.0,,isolates,important,CLSI 2018,,,amr_prevalence,,wound_swab,,,,,5,hospital,,,,,mm,Misha2021-Ethiopia-JimmaMedicalCenter-2019-01,Multi-drug resistance (MDR) to commonly used antibiotics was identified.,Staphylococcus aureus
4,disk_diffusion,,Ethiopia,,,,amr_prevalence,CLSI,erythromycin,2019.0,,tertiary,2019.0,,isolates,important,CLSI 2018,,,amr_prevalence,,wound_swab,,,,,5,hospital,,,,,mm,Misha2021-Ethiopia-JimmaMedicalCenter-2019-01,Multi-drug resistance (MDR) to commonly used antibiotics was identified.,Staphylococcus aureus
4,disk_diffusion,,Ethiopia,,,,amr_prevalence,CLSI,clindamycin,2019.0,,tertiary,2019.0,,isolates,important,CLSI 2018,,,amr_prevalence,,wound_swab,,,,,5,hospital,,,,,mm,Misha2021-Ethiopia-JimmaMedicalCenter-2019-01,Multi-drug resistance (MDR) to commonly used antibiotics was identified.,Staphylococcus aureus
0,disk_diffusion,,Ethiopia,,,,amr_prevalence,CLSI,meropenem,2019.0,,tertiary,2019.0,,isolates,critically_important,CLSI 2018,,,amr_prevalence,,wound_swab,,,,,9,hospital,,,,,mm,Misha2021-Ethiopia-JimmaMedicalCenter-2019-01,Multi-drug resistance (MDR) to commonly used antibiotics was identified.,Escherichia coli
8,disk_diffusion,,Ethiopia,,,,amr_prevalence,CLSI,ceftriaxone,2019.0,,tertiary,2019.0,,isolates,critically_important,CLSI 2018,,,amr_prevalence,,wound_swab,,,,,8,hospital,,,,,mm,Misha2021-Ethiopia-JimmaMedicalCenter-2019-01,Multi-drug resistance (MDR) to commonly used antibiotics was identified.,Pseudomonas aeruginosa
6,disk_diffusion,,Ethiopia,,,,amr_prevalence,CLSI,ceftriaxone,2019.0,,tertiary,2019.0,,isolates,critically_important,CLSI 2018,,,amr_prevalence,,wound_swab,,,,,6,hospital,,,,,mm,Misha2021-Ethiopia-JimmaMedicalCenter-2019-01,Multi-drug resistance (MDR) to commonly used antibiotics was identified.,Proteus spp.
34,disk_diffusion,,Tanzania,,,,amr_prevalence,EUCAST,oxacillin,2013.0,,tertiary,2013.0,,isolates,critically_important,"Version 5.0, 2015",,,amr_prevalence,,wound_swab,,,diffusion method with oxacillin disc,,43,hospital,,,,,,DeNardo2016-Tanzania-Dodoma-2013-1,,Staphylococcus aureus
26,disk_diffusion,,Ethiopia,25.0,double-disc synergy test,4.0,amr_prevalence,CLSI,cefepime,2022.0,,tertiary,2022.0,,isolates,critically_important,CLSI 2021,,,amr_prevalence,14.0,wound_swab,,,,,29,hospital,11,modified Hodge test,,"NDM (2), KPC (1)",mm,Odoko2024-Ethiopia-SodoHospitals-2022-01,MDR: resistant to at least one agent in three or more antimicrobial categories.,Escherichia coli
14,disk_diffusion,,Ethiopia,7.0,double-disc synergy test,7.0,amr_prevalence,CLSI,cefepime,2022.0,,tertiary,2022.0,,isolates,critically_important,CLSI 2021,,,amr_prevalence,3.0,wound_swab,,,,,14,hospital,10,modified Hodge test,,,mm,Odoko2024-Ethiopia-SodoHospitals-2022-01,MDR: resistant to at least one agent in three or more antimicrobial categories.,Klebsiella pneumoniae
4,disk_diffusion,,Ethiopia,25.0,double-disc synergy test,4.0,amr_prevalence,CLSI,meropenem,2022.0,,tertiary,2022.0,,isolates,critically_important,CLSI 2021,,,amr_prevalence,14.0,wound_swab,,,,,29,hospital,11,modified Hodge test,,"NDM (2), KPC (1)",mm,Odoko2024-Ethiopia-SodoHospitals-2022-01,MDR: resistant to at least one agent in three or more antimicrobial categories.,Escherichia coli
9,disk_diffusion,,Ethiopia,7.0,double-disc synergy test,7.0,amr_prevalence,CLSI,meropenem,2022.0,,tertiary,2022.0,,isolates,critically_important,CLSI 2021,,,amr_prevalence,3.0,wound_swab,,,,,14,hospital,10,modified Hodge test,,,mm,Odoko2024-Ethiopia-SodoHospitals-2022-01,MDR: resistant to at least one agent in three or more antimicrobial categories.,Klebsiella pneumoniae
12,disk_diffusion,,Uganda,,,,amr_prevalence,CLSI,ciprofloxacin,2007.0,,tertiary,2007.0,,isolates,critically_important,CLSI 2003,,,amr_prevalence,,wound_swab,,,PCR,,17,hospital,,,,,mm,Ojulong2009-Uganda-Mulago-2007-01,,Staphylococcus aureus
0,disk_diffusion,,Uganda,,,,amr_prevalence,CLSI,vancomycin,2007.0,,tertiary,2007.0,,isolates,critically_important,CLSI 2003,,,amr_prevalence,,wound_swab,,,PCR,,17,hospital,,,,,mm,Ojulong2009-Uganda-Mulago-2007-01,,Staphylococcus aureus
0,disk_diffusion,erm gene (inducible resistance),Uganda,,,,amr_prevalence,CLSI,clindamycin,2007.0,,tertiary,2007.0,,isolates,critically_important,CLSI 2003,,,amr_prevalence,,wound_swab,,,PCR,,17,hospital,,,,,mm,Ojulong2009-Uganda-Mulago-2007-01,Inducible clindamycin resistance detected by D-test; 82.4% positive.,Staphylococcus aureus
10,disk_diffusion,,Uganda,,,,amr_prevalence,CLSI,gentamicin,2007.0,,tertiary,2007.0,,isolates,critically_important,CLSI 2003,,,amr_prevalence,,wound_swab,,,PCR,,17,hospital,,,,,mm,Ojulong2009-Uganda-Mulago-2007-01,,Staphylococcus aureus
15,disk_diffusion,,Uganda,,,,amr_prevalence,CLSI,co-trimoxazole,2007.0,,tertiary,2007.0,,isolates,highly_important,CLSI 2003,,,amr_prevalence,,wound_swab,,,PCR,,17,hospital,,,,,mm,Ojulong2009-Uganda-Mulago-2007-01,,Staphylococcus aureus
15,disk_diffusion,,Uganda,,,,amr_prevalence,CLSI,chloramphenicol,2007.0,,tertiary,2007.0,,isolates,highly_important,CLSI 2003,,,amr_prevalence,,wound_swab,,,PCR,,17,hospital,,,,,mm,Ojulong2009-Uganda-Mulago-2007-01,,Staphylococcus aureus
15,disk_diffusion,,Uganda,,,,amr_prevalence,CLSI,erythromycin,2007.0,,tertiary,2007.0,,isolates,critically_important,CLSI 2003,,,amr_prevalence,,wound_swab,,,PCR,,17,hospital,,,,,mm,Ojulong2009-Uganda-Mulago-2007-01,,Staphylococcus aureus
17,"oxacillin agar screen, PCR for mecA",mecA,Uganda,,,,amr_prevalence,CLSI,oxacillin,2007.0,,tertiary,2007.0,,isolates,critically_important,NCCLS 2003,,,amr_prevalence,,wound_swab,,,PCR for mecA gene,,54,hospital,,,,,,Ojulong2009-Uganda-Mulago-2007-01,,Staphylococcus aureus
0,MIC_broth,,Gabon,,,,amr_prevalence,CLSI,cloxacillin,2009.0,,tertiary,2009.0,,isolates,important,CLSI 2007,,,amr_prevalence,,wound_swab,,,PBP2a-agglutination test for cefoxitin-resistant S. aureus,,14,hospital,,,,,,Scherbaum2014-Gabon-Lambarene-2009-01,,Staphylococcus aureus
13,MIC_broth,,Gabon,5.0,double-disks method,,amr_prevalence,CLSI,ampicillin,2009.0,,tertiary,2009.0,,isolates,important,CLSI 2007,,,amr_prevalence,5.0,urine,,,,,14,hospital,,,,,,Scherbaum2014-Gabon-Lambarene-2009-01,ESBL production confirmed by double-disks method.,Escherichia coli
5,MIC_broth,,Gabon,5.0,double-disks method,,amr_prevalence,CLSI,ceftriaxone,2009.0,,tertiary,2009.0,,isolates,critically_important,CLSI 2007,,,amr_prevalence,5.0,urine,,,,,14,hospital,,,,,,Scherbaum2014-Gabon-Lambarene-2009-01,ESBL production confirmed by double-disks method.,Escherichia coli
3,MIC_broth,,Gabon,3.0,double-disks method,,amr_prevalence,CLSI,ceftriaxone,2009.0,,tertiary,2009.0,,isolates,critically_important,CLSI 2007,,,amr_prevalence,3.0,urine,,,,,6,hospital,,,,,,Scherbaum2014-Gabon-Lambarene-2009-01,ESBL production confirmed by double-disks method.,Klebsiella pneumoniae
3,VITEK2,,Rwanda,,,,amr_prevalence,study_defined,ceftriaxone,2019.0,,secondary,2020.0,,isolates,critically_important,,,,amr_prevalence,,wound_swab,,,,,3,hospital,,,,,,Velin2021-Rwanda-KireheDistrictHospital-2019_2020-01,,Escherichia coli
8,VITEK2,,Rwanda,,,,amr_prevalence,study_defined,ceftriaxone,2019.0,,secondary,2020.0,,isolates,critically_important,,,,amr_prevalence,,wound_swab,,,,,8,hospital,,,,,,Velin2021-Rwanda-KireheDistrictHospital-2019_2020-01,,Klebsiella pneumoniae
7,VITEK2,,Rwanda,,,,amr_prevalence,study_defined,ceftriaxone,2019.0,,secondary,2020.0,,isolates,critically_important,,,,amr_prevalence,,wound_swab,,,,,8,hospital,,,,,,Velin2021-Rwanda-KireheDistrictHospital-2019_2020-01,,Proteus spp.
8,VITEK2,,Rwanda,,,,amr_prevalence,study_defined,ceftriaxone,2019.0,,secondary,2020.0,,isolates,critically_important,,,,amr_prevalence,,wound_swab,,,,,8,hospital,,,,,,Velin2021-Rwanda-KireheDistrictHospital-2019_2020-01,,Enterobacter cloacae complex
9,VITEK2,,Rwanda,,,,amr_prevalence,study_defined,ceftriaxone,2019.0,,secondary,2020.0,,isolates,critically_important,,,,amr_prevalence,,wound_swab,,,,,9,hospital,,,,,,Velin2021-Rwanda-KireheDistrictHospital-2019_2020-01,,Acinetobacter baumannii complex
2,VITEK2,,Rwanda,,,,amr_prevalence,study_defined,cefoxitin,2019.0,,secondary,2020.0,,isolates,critically_important,,,,amr_prevalence,,wound_swab,,,cefoxitin resistance by VITEK2,,2,hospital,,,,,,Velin2021-Rwanda-KireheDistrictHospital-2019_2020-01,MRSA defined as resistance to cefoxitin.,Staphylococcus aureus
43,disk_diffusion,,Uganda,,disc diffusion with ceftazidime/clavulanate,15.0,amr_prevalence,CLSI,ceftriaxone,2017.0,,tertiary,2018.0,,isolates,critically_important,CLSI 2017,,,amr_prevalence,,wound_swab,,,,,44,hospital,,phenotypic (carbapenem resistance),,,mm,Wekesa2020-Uganda-MulagoHospital-201711201804-01,,Klebsiella species
40,disk_diffusion,,Uganda,19.0,disc diffusion with ceftazidime/clavulanate,15.0,amr_prevalence,CLSI,ceftazidime,2017.0,,tertiary,2018.0,,isolates,critically_important,CLSI 2017,,,amr_prevalence,,wound_swab,,,,,44,hospital,,phenotypic (carbapenem resistance),,,mm,Wekesa2020-Uganda-MulagoHospital-201711201804-01,,Klebsiella species
11,disk_diffusion,,Uganda,,disc diffusion with ceftazidime/clavulanate,0.0,amr_prevalence,CLSI,ceftriaxone,2017.0,,tertiary,2018.0,,isolates,critically_important,CLSI 2017,,,amr_prevalence,,wound_swab,,,,,11,hospital,,,,,mm,Wekesa2020-Uganda-MulagoHospital-201711201804-01,,Escherichia coli
11,disk_diffusion,,Uganda,10.0,disc diffusion with ceftazidime/clavulanate,0.0,amr_prevalence,CLSI,ceftazidime,2017.0,,tertiary,2018.0,,isolates,critically_important,CLSI 2017,,,amr_prevalence,,wound_swab,,,,,11,hospital,,,,,mm,Wekesa2020-Uganda-MulagoHospital-201711201804-01,,Escherichia coli
31,PCR (mecA gene),mecA,Uganda,,,,amr_prevalence,study_defined,methicillin,2017.0,,tertiary,2018.0,,isolates,critically_important,,,,amr_prevalence,,wound_swab,,,PCR for mecA gene,,34,hospital,,,,,,Wekesa2020-Uganda-MulagoHospital-201711201804-01,,Staphylococcus aureus
41,disk_diffusion,"blaCTX−M, blaTEM, blaOXA, blaNDM",Ethiopia,40.0,Combination Disk Test (CDT),,amr_prevalence,CLSI,ceftriaxone,2020.0,,tertiary,2021.0,,isolates,critically_important,CLSI 2021,,,amr_prevalence,,wound_swab,,,,,43,hospital,,PCR and sequencing,,"blaOXA, blaNDM",mm,Worku2024-Ethiopia-Multicenter-2020-2021-1,,Acinetobacter baumannii
41,disk_diffusion,,Ethiopia,,Combination Disk Test (CDT),,amr_prevalence,CLSI,ceftazidime,2020.0,,tertiary,2021.0,,isolates,critically_important,CLSI 2021,,,amr_prevalence,,wound_swab,,,,,43,hospital,,,,,mm,Worku2024-Ethiopia-Multicenter-2020-2021-1,,Acinetobacter baumannii
37,disk_diffusion,"blaOXA, blaNDM",Ethiopia,,,37.0,amr_prevalence,CLSI,imipenem,2020.0,,tertiary,2021.0,,isolates,critically_important,CLSI 2021,,,amr_prevalence,,wound_swab,,,,,43,hospital,,PCR and sequencing,,"blaOXA, blaNDM",mm,Worku2024-Ethiopia-Multicenter-2020-2021-1,,Acinetobacter baumannii
138,disk_diffusion,,Ethiopia,,,,amr_prevalence,CLSI,penicillin,2020.0,,tertiary,2021.0,,isolates,important,CLSI 2021,,,amr_prevalence,153.0,wound_swab,,,Cefoxitin disk as surrogate marker,,153,hospital,,,,,mm,Worku2023-Ethiopia-Multicentre-2020-2021-1,Resistance to at least one drug in three or more categories.,Staphylococcus aureus
117,disk_diffusion,,Ethiopia,,,,amr_prevalence,CLSI,ampicillin,2020.0,,tertiary,2021.0,,isolates,important,CLSI 2021,,,amr_prevalence,153.0,wound_swab,,,Cefoxitin disk as surrogate marker,,153,hospital,,,,,mm,Worku2023-Ethiopia-Multicentre-2020-2021-1,Resistance to at least one drug in three or more categories.,Staphylococcus aureus
0,disk_diffusion,,Ethiopia,,,,amr_prevalence,CLSI,vancomycin,2020.0,,tertiary,2021.0,,isolates,critically_important,CLSI 2021,,,amr_prevalence,153.0,wound_swab,,,Cefoxitin disk as surrogate marker,,153,hospital,,,,,mm,Worku2023-Ethiopia-Multicentre-2020-2021-1,Resistance to at least one drug in three or more categories.,Staphylococcus aureus
96,disk_diffusion,,Ethiopia,,,,amr_prevalence,CLSI,ampicillin,2020.0,,tertiary,2021.0,,isolates,important,CLSI 2021,,,amr_prevalence,98.0,wound_swab,,,,,102,hospital,,,,,mm,Worku2023-Ethiopia-Multicentre-2020-2021-1,Resistance to at least one drug in three or more categories.,Escherichia coli
101,disk_diffusion,,Ethiopia,,,,amr_prevalence,CLSI,ceftriaxone,2020.0,,tertiary,2021.0,,isolates,critically_important,CLSI 2021,,,amr_prevalence,98.0,wound_swab,,,,,102,hospital,,,,,mm,Worku2023-Ethiopia-Multicentre-2020-2021-1,Resistance to at least one drug in three or more categories.,Escherichia coli
12,disk_diffusion,,Ethiopia,,,,amr_prevalence,CLSI,imipenem,2020.0,,tertiary,2021.0,,isolates,critically_important,CLSI 2021,,,amr_prevalence,98.0,wound_swab,,,,,102,hospital,,,,,mm,Worku2023-Ethiopia-Multicentre-2020-2021-1,Resistance to at least one drug in three or more categories.,Escherichia coli
40,disk_diffusion,"mecA, femA, vanA, vanB",Ethiopia,,,,amr_prevalence,CLSI,cefoxitin,2020.0,,tertiary,2021.0,,isolates,critically_important,CLSI 2021,8,,amr_prevalence,,wound_swab,,,Cefoxitin disk diffusion and mecA PCR,,163,hospital,,,µg/mL,,mm,Worku2023-Ethiopia-FourHospitals-2020-2021-1,,Staphylococcus aureus
1,MIC_broth,"vanA, vanB",Ethiopia,,,,amr_prevalence,CLSI,vancomycin,2020.0,,tertiary,2021.0,,isolates,critically_important,CLSI 2021,8,,amr_prevalence,,wound_swab,,,,,40,hospital,,,µg/mL,,,Worku2023-Ethiopia-FourHospitals-2020-2021-1,,Staphylococcus aureus
